These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 27060634)

  • 21. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.
    Kiefer JD; Neri D
    Immunol Rev; 2016 Mar; 270(1):178-92. PubMed ID: 26864112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunocytokines: a promising approach to cancer immunotherapy.
    Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
    Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
    Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
    Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
    Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
    Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in cancer immunotherapy.
    Ockert D; Schmitz M; Hampl M; Rieber EP
    Immunol Today; 1999 Feb; 20(2):63-5. PubMed ID: 10098323
    [No Abstract]   [Full Text] [Related]  

  • 27. Antibody-directed, effector cell-mediated tumor destruction.
    Sondel PM; Hank JA
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):703-21. PubMed ID: 11676280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
    Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-cytokine fusion proteins: applications in cancer therapy.
    Ortiz-Sánchez E; Helguera G; Daniels TR; Penichet ML
    Expert Opin Biol Ther; 2008 May; 8(5):609-32. PubMed ID: 18407765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.
    Bootz F; Neri D
    Drug Discov Today; 2016 Jan; 21(1):180-189. PubMed ID: 26526566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
    Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
    J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis.
    Hombach A; Heuser C; Abken H
    Int J Cancer; 2005 Jun; 115(2):241-7. PubMed ID: 15688386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
    Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
    Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy: Progress and challenges in the clinical setting.
    Zarour HM; Ferrone S
    Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.